OncBioMune Receives Notice of Patent Allowance for Novel Cancer Vaccine ProscaVax(TM) in Mexico
OncBioMune Pharmaceuticals (OTCMKTS:OBMP), a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, today announces that the Company has received a Notice of Allowance from the Mexican Institute of Industrial Property for OncBioMune’s patent application number MX/a/2013/008188.
OncBioMune Pharmaceuticals (OTCMKTS:OBMP), a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, today announces that the Company has received a Notice of Allowance from the Mexican Institute of Industrial Property for OncBioMune’s patent application number MX/a/2013/008188. The patent covers ProscaVax™, OncBioMune’s novel cancer vaccine in clinical development, as a composition and method for treating cancer.
ProscaVax is a novel protein therapeutic cancer vaccine combining tumor-associated antigens with biological adjuvants to selectively target tumor cells without damage to healthy cells. OncBioMune and its Mexican Joint Venture partner Vitel Laboratorios S.A. de C.V. (“Vitel”) are sponsoring a Phase 2/3 clinical study of ProscaVax in Mexico evaluating the vaccine as a new treatment for recurrent prostate cancer in hormone-naïve and hormone-independent patients.
“We are very pleased to receive notice of allowance of another patent covering ProscaVax. The patent in Mexico is particularly important because if the endpoints are met in the Phase 2/3 study, we intend to seek marketing approval through Mexico’s expedited approval process,” commented Dr. Jonathan Head, Chief Executive Officer at OncBioMune. “Moreover, as with other patents pertaining to ProscaVax, the patent claims are broad enough to cover many other types of cancer that we intend to research in Mexico in the future.”
The latest patent expands the protection of ProscaVax and other OncBioMune intellectual property to 16 patents spanning approximately 50 countries worldwide.
Connect with OncBioMune Pharmaceuticals (OTCMKTS:OBMP) to receive an Investor Presentation.